Subject: SmithKline Finds Agent That Seems To Hamper AIDS Date: Published: 12/17/87 43 lines Source: WALL STREET JOURNAL. Copyright Dow Jones & Co. Inc. SmithKline Finds Agent That Seems To Hamper AIDS PHILADELPHIA -- SmithKline Beckman Corp. said it developed a protein agent that appears to block the AIDS virus and prevents it from spreading and infecting healthy cells. Laboratory tests suggest the substance could lead to a new drug for treating the disease, the pharmaceutical concern said. However, SmithKline emphasized it hasn't tested the protein in humans yet and said it won't be ready for wide-scale trials on AIDS patients for at least three years. The protein, known as soluble T4 receptor, blocks the principal routes used by the AIDS virus to infect human cells. The discovery, if true, would be significant because scientists have found that when the acquired immune deficiency syndrome virus enters the bloodstream, it takes over and destroys the cells that regulate the body's immune system. The victim then becomes susceptible to deadly infections. Results of laboratory tests have been submitted to Nature for publication next month, a SmithKline spokesman said. SmithKline began the work more than a year ago with scientists at Columbia University. SmithKline is but one of several groups currently exploring the T4 receptor molecule as a possible therapy. A group at Genentech Inc., the South San Francisco, Calif., biotechnology concern, is slated to publish the first major scientific paper on the potential therapy tomorrow in the journal Science. Yesterday in New York Stock Exchange composite trading, SmithKline closed at $47.25, up 12.5 cents. In national over-the-counter trading, Genentech rose $2.50 to $38.50. [This article is made available here by Dow Jones Co. for the personal and non-commercial use of callers to this bbs, in the hope that it will be of some help to those who are suffering from the disease and others who are seeking to help them.]